Transactions

Overview
Mind Medicine (MindMed) Inc. Completes $34.5 Million Bought Deal Prospectus Offering
December 11, 2020Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness, completed a bought deal prospectus offering of 18,170,000 units for aggregate gross proceeds of $34,523,000. The offering was conducted by Canaccord Genuity Corp., as lead underwriter, and Eight Capital.
Wildeboer Dellelce LLP acted for MindMed in connection with the offering with a team comprised of Perry Dellelce, Peter Volk, Rebecca Cochrane and Katie Drury (corporate/securities) and Katy Pitch and Marija Tasevska (tax).
Client
Mind Medicine (MindMed) Inc.
Visit website »
Wildeboer Dellelce Team
Related transactions
Mind Medicine (MindMed) Inc. Completes Nasdaq Up-Listing
April 28, 2021
Mind Medicine (MindMed) Inc. Completes Acquisition of HealthMode, Inc.
March 22, 2021
Mind Medicine (MindMed) Inc. Completes $19.5 Million Bought Deal Private Placement
March 08, 2021